Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation

Table 1 Study population characteristics n (%)

n	358
Gender (M/F)	281 (78.5)/77 (21.5)
Age at LT (yr, mean ± SD)	52 ± 9
Donor age (yr, mean ± SD)	53 ± 17
HCV Genotype
1	212 (59.2)
2	48 (13.4)
3	57 (15.9)
4	41 (11.5)
Immunosuppression
Cyclosporine	269 (75.1)
Tacrolimus	83 (23.2)
Other regimens	6 (1.7)
Antiviral therapy after LT
Treated	150 (41.9)
Untreated	208 (58.1)

HCV: Hepatitis C virus; LT: Liver transplantation.

Table 2 Characteristics of treated and untreated patients n (%)

	Treated	Untreated	χ2/Mann Whitney-U
n	150	208
Gender (M/F)	120/30	161/47	P = NS
Age at LT (yr, mean ± SD)	52 ± 8	52 ± 9	P = NS
Donor age (yr, mean ± SD)	53 ± 17	53 ± 17	P = NS
HCV genotype			P = NS
1	97 (64.7)	115 (55.3)
2	16 (10.7)	35 (16.8)
3	25 (16.6)	35 (16.8)
4	12 (8.0)	23 (11.1)
Immunosuppression			P = 0.011
Cyclosporine	102 (68.0)	165 (79.3)
Tacrolimus	46 (30.7)	39 (18.8)
Other regimens	2 (1.3)	4 (1.9)

HCV: Hepatitis C virus; NS: Not significant.

Table 3 Characteristics of patients divided by groups

Group	A	B	C	D	E	χ2/Kruskall Wallis
	SVR	NR	Mild recurrence	Too sick	Comorbidity
n	63	87	73	35	100
Gender (M/F)	47/16	73/14	63/10	20/15	78/22	P = 0.007
Age at LT (yr, mean ± SD)	52 ± 8	52 ± 9	53 ± 8	52 ± 9	51 ± 9	P = NS
Donor age (yr, mean ± SD)	49 ± 17	56 ± 15	48 ± 17	59 ± 15	55 ± 17	P = 0.001
HCV genotype						P = NS
1	37	60	45	16	44
2	7	6	9	3	13
3	9	13	6	5	14
4	8	5	7	1	10
Immunosuppression	48	55	54	24	83	P = NS
Cyclosporine	14	31	16	10	13
Tacrolimus	1	1	3	1	4
Other regimens
Time between treatment start and LT [mo, median (min-max)]	20 (1-148)	16 (1-117)				P = NS
Treatment Length [mo, median (min-max)]	11 (1-61)	6 (1-63)				P = 0.010

SVR: Sustained virological response; NR: Non-response; HCV: Hepatitis C virus; NS: Not significant; LT: Liver transplantation.

Table 4 Causes of death

Group	A	B	C	D	E
	SVR	NR	Mild recurrence	Too sick	Comorbidity
n	63	87	73	35	100
No. of deaths at 10 yr after LT, n (%)	7 (11.1)	35 (40.2)	6 (8.2)	35 (100)	20 (20)
Liver related, n (%)	2 (28.6)	22 (62.9)	3 (50)	11 (31.4)	10 (50)
HCV recurrence	1	17	2	3	1
HCC	1	4	1	1	8
Primary non function	0	0	0	6	0
Other liver-related	0	1	0	1	1
Non liver-related, n (%)	5 (71.4)	13 (37.1)	3 (50)	24 (68.6)	10 (50)
Cardiac	1	0	0	0	0
Renal	0	2	0	0	0
Cancer	0	1	0	3	6
Infection	0	6	1	10	3
Vascular	0	0	1	0	0
Other comorbidity	4	4	1	11	1

SVR: Sustained virological response; HCC: Hepatocellular carcinoma; NR: Non-response; LT: Liver transplantation.